Dynavax To Seek Experienced Vaccines Partner To Commercialize Heplisav

The company reports positive Phase III data for the hepatitis B vaccine showing 98.5% seroprotection after two doses.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet